NASDAQ:BBIO BridgeBio Pharma Q4 2024 Earnings Results & Report $79.33 +1.40 (+1.80%) As of 03:00 PM Eastern This is a fair market value price provided by Massive. Learn more. BridgeBio Pharma missed analyst earnings expectations but beat on revenue in its Q4 2024 results, released February 20, 2025. The company reported EPS of -$1.31 versus the -$1.09 consensus estimate, while revenue of $5.88 million topped the $4.04 million estimate by $1.84 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateFebruary 20, 2025TimeBefore Market OpensConference Call12:30 PM ET BridgeBio Pharma EPS ResultsActual EPS-$1.31Consensus EPS -$1.09Beat/MissMissed by -$0.22One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersBridgeBio Pharma Revenue ResultsActual Revenue$5.88 millionExpected Revenue$4.04 millionBeat/MissBeat by +$1.84 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) BridgeBio Pharma Q4 2024 Earnings FAQ Did BridgeBio Pharma beat earnings estimates for Q4 2024? BridgeBio Pharma (NASDAQ:BBIO) reported earnings of -$1.31 per share for Q4 2024, missing the consensus estimate of -$1.09. The report was announced on Thursday, February 20, 2025. What was BridgeBio Pharma's revenue for Q4 2024? BridgeBio Pharma reported revenue of $5.88 million for Q4 2024, against a consensus estimate of $4.04 million. BridgeBio Pharma Earnings HeadlinesBridgeBio to Participate in November and December Investor ConferencesNovember 9 at 7:30 AM | globenewswire.comBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)November 6, 2026 | globenewswire.comExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December. The agenda at the upcoming G20 Summit in Miami has shifted, and new research points to a major monetary announcement from President Trump. A new documentary breaks down what this shift could mean for savings, investments, and the assets tied to it.November 10 at 1:00 AM | Porter & Company (Ad)BridgeBio Pharma (NASDAQ:BBIO) Stock Gets Price Target Increase from Canaccord Genuity GroupNovember 4, 2026 | americanbankingnews.comBarclays Keeps Their Buy Rating on BridgeBio Pharma (BBIO)November 3, 2026 | theglobeandmail.comBridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026November 3, 2026 | globenewswire.comSee More BridgeBio Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BridgeBio Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BridgeBio Pharma and other key companies, straight to your email. Email Address About BridgeBio PharmaBridgeBio Pharma (NASDAQ:BBIO) is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions. BridgeBio is headquartered in Palo Alto, California. Co-founder Neil Kumar serves as the company’s chief executive officer.View BridgeBio Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
